📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The evolving use of measurable residual disease in chronic lymphocytic leukemia clinical trials. (2023)

First Author: Fisher A

Attributed to: Chronic Lymphocytic Leukaemia: uncovering immunity during first-line treatment funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3389/fonc.2023.1130617

PubMed Identifier: 36910619

Publication URI: http://europepmc.org/abstract/MED/36910619

Type: Journal Article/Review

Volume: 13

Parent Publication: Frontiers in oncology

ISSN: 2234-943X